[1]
|
Stein, J.D., Khawaja, A.P. and Weizer, J.S. (2021) Glaucoma in Adults—Screening, Diagnosis, and Management. JAMA, 325, 164-174. https://doi.org/10.1001/jama.2020.21899
|
[2]
|
Bourne, R.R.A., Flaxman, S.R., Braithwaite, T., Cicinelli, M.V., Das, A., Jonas, J.B., Keeffe, J., Kempen, J.H., Leasher, J., Limburg, H., Naidoo, K., Pesudovs, K., Resnikoff, S., Silvester, A., Stevens, G.A., Tahhan, N., Wong, T.Y., Taylor, H.R. and Vision Loss Expert, G. (2017) Magnitude, Temporal Trends, and Projections of the Global Prevalence of Blindness and Distance and Near Vision Impairment: A Systematic Review and Meta-Analysis. The Lancet Global Health, 5, e888-e897. https://doi.org/10.1016/S2214-109X(17)30293-0
|
[3]
|
Allison, K., Patel, D. and Alabi, O. (2020) Epidemiology of Glaucoma: The Past, Present, and Predictions for the Future. Cureus, 12, e11686. https://doi.org/10.7759/cureus.11686
|
[4]
|
Song, P., Wang, J., Bucan, K., Theodoratou, E., Rudan, I. and Chan, K.Y. (2017) National and Subnational Prevalence and Burden of Glaucoma in China: A Systematic Analysis. Journal of Global Health, 7, Article ID: 020705.
https://doi.org/10.7189/jogh.07.020705
|
[5]
|
Webb, T.E.R. (2021) A Review of Glaucoma Surgical Therapy. Veterinary Ophthalmology, 24, 34-38.
https://doi.org/10.1111/vop.12852
|
[6]
|
Razeghinejad, M.R. and Lee, D. (2019) Managing Normal Tension Glaucoma by Lowering the Intraocular Pressure. Survey of Ophthalmology, 64, 111-116. https://doi.org/10.1016/j.survophthal.2018.07.003
|
[7]
|
Guglielmi, P., Carradori, S., Campestre, C. and Poce, G. (2019) Novel Therapies for Glaucoma: A Patent Review (2013- 2019). Expert Opinion on Therapeutic Patents, 29, 769-780. https://doi.org/10.1080/13543776.2019.1653279
|
[8]
|
Angeli, A. and Supuran, C.T. (2019) Prostaglandin Receptor Agonists as Antiglaucoma Agents (a Patent Review 2013- 2018). Expert Opinion on Therapeutic Patents, 29, 793-803. https://doi.org/10.1080/13543776.2019.1661992
|
[9]
|
Aihara, M. (2021) Prostanoid Receptor Agonists for Glaucoma Treatment. Japanese Journal of Ophthalmology, 65, 581-590. https://doi.org/10.1007/s10384-021-00844-6
|
[10]
|
Hellberg, M.R., McLaughlin, M.A., Sharif, N.A., DeSantis, L., Dean, T.R., Kyba, E.P., Bishop, J.E., Klimko, P.G., Zinke, P.W., Selliah, R.D., Barnes, G., DeFaller, J., Kothe, A., Landry, T., Sullivan, E.K., Andrew, R., Davis, A.A., Silver, L., Bergamini, M.V., Robertson, S., Weiner, A.L. and Sallee, V.L. (2002) Identification and Characterization of the Ocular Hypotensive Efficacy of Travoprost, a Potent and Selective FP Prostaglandin Receptor Agonist, and AL-6598, a DP Prostaglandin Receptor Agonist. Survey of Ophthalmology, 47, S13-S33.
https://doi.org/10.1016/S0039-6257(02)00293-X
|
[11]
|
Ota, T., Aihara, M., Narumiya, S. and Araie, M. (2005) The Effects of Prostaglandin Analogues on IOP in Prostanoid FP-Receptor-Deficient Mice. Investigative Ophthalmology & Visual Science, 46, 4159-4163.
https://doi.org/10.1167/iovs.05-0494
|
[12]
|
Ota, T., Aihara, M., Saeki, T., Narumiya, S. and Araie, M. (2006) The Effects of Prostaglandin Analogues on Prostanoid EP1, EP2, and EP3 Receptor-Deficient Mice. Investigative Ophthalmology & Visual Science, 47, 3395-3399.
https://doi.org/10.1167/iovs.06-0100
|
[13]
|
Saeki, T., Ota, T., Aihara, M. and Araie, M. (2009) Effects of Prostanoid EP Agonists on Mouse Intraocular Pressure. Investigative Ophthalmology & Visual Science, 50, 2201-2208. https://doi.org/10.1167/iovs.08-2800
|
[14]
|
Winkler, N.S. and Fautsch, M.P. (2014) Effects of Prostaglandin Analogues on Aqueous Humor Outflow Pathways. Journal of Ocular Pharmacology and Therapeutics, 30, 102-109. https://doi.org/10.1089/jop.2013.0179
|
[15]
|
Honrubia, F., García-Sánchez, J. and Polo, V. (2009) Conjunctival Hyperaemia with the Use of Latanoprost versus Other Prostaglandin Analogues in Patients with Ocular Hypertension or Glaucoma: A Meta-Analysis of Randomised Clinical Trials. British Journal of Ophthalmology, 93, 316. https://doi.org/10.1136/bjo.2007.135111
|
[16]
|
Taketani, Y., Yamagishi, R., Fujishiro, T., Igarashi, M., Sakata, R. and Aihara, M. (2014) Activation of the Prostanoid FP Receptor Inhibits Adipogenesis Leading to Deepening of the Upper Eyelid Sulcus in Prostaglandin-Associated Periorbitopathy. Investigative Ophthalmology & Visual Science, 55, 1269-1276. https://doi.org/10.1167/iovs.13-12589
|
[17]
|
Krishnamurthy, R., Senthil, S. and Garudadri, C.S. (2015) Late Postoperative Choroidal Detachment Following an Uneventful Cataract Surgery in a Patient on Topical Latanoprost. BMJ Case Reports, 2015, bcr2015211408.
https://doi.org/10.1136/bcr-2015-211408
|
[18]
|
Bitton, E.O.D.M.F.F., Courey, C.O.D.F., Giancola, P.O.D., Diaconu, V.P., Wise, J.M.D. and Wittich, W.P.F.C. (2017) Effects of LATISSE (Bimatoprost 0.03 Percent Topical Solution) on the Ocular Surface. Clinical and Experimental Optometry, 100, 583-589. https://doi.org/10.1111/cxo.12507
|
[19]
|
Jayanetti, V., Sandhu, S. and Lusthaus, J.A. (2020) The Latest Drugs in Development That Reduce Intraocular Pressure in Ocular Hypertension and Glaucoma. Journal of Experimental Pharmacology, 12, 539-548.
https://doi.org/10.2147/JEP.S281187
|
[20]
|
Duggan, S. (2018) Omidenepag Isopropyl Ophthalmic Solution 0.002%: First Global Approval. Drugs, 78, 1925-1929.
https://doi.org/10.1007/s40265-018-1016-1
|
[21]
|
Weinreb, R.N., Liebmann, J.M. and Martin, K.R. (2018) Latanoprostene Bunod 0.024% in Subjects with Open-Angle Glaucoma or Ocular Hypertension: Pooled Phase 3 Study Findings. Journal of Glaucoma, 27, 7-15.
https://doi.org/10.1097/IJG.0000000000000831
|
[22]
|
Tong, L., Matsuura, E., Takahashi, M., Nagano, T. and Kawazu, K. (2019) Effects of Anti-Glaucoma Prostaglandin Ophthalmic Solutions on Cultured Human Corneal Epithelial Cells. Current Eye Research, 44, 856-862.
https://doi.org/10.1080/02713683.2019.1597127
|
[23]
|
Lee, H.J., Jun, R.M., Cho, M.S. and Choi, K.-R. (2015) Comparison of the Ocular Surface Changes Following the Use of Two Different Prostaglandin F2α Analogues Containing Benzalkonium Chloride or Polyquad in Rabbit Eyes. Cutaneous and Ocular Toxicology, 34, 195-202. https://doi.org/10.3109/15569527.2014.944650
|
[24]
|
Nam, M. and Kim, S.W. (2021) Changes in Corneal Epithelial Thickness Induced by Topical Antiglaucoma Medications. Journal of Clinical Medicine, 10, 3464. https://doi.org/10.3390/jcm10163464
|
[25]
|
Takada, Y., Yamanaka, O., Okada, Y., Sumioka, T., Reinach, P.S. and Saika, S. (2020) Effects of a Prostaglandin F2alpha Derivative Glaucoma Drug on EGF Expression and E-cadherin Expression in a Corneal Epithelial Cell Line. Cutaneous and Ocular Toxicology, 39, 75-82. https://doi.org/10.1080/15569527.2020.1722152
|
[26]
|
Bergonzi, C., Giani, A., Blini, M., Marchi, S., Luccarelli, S. and Staurenghi, G. (2010) Evaluation of Prostaglandin Analogue Effects on Corneal Keratocyte Density Using Scanning Laser Confocal Microscopy. Journal of Glaucoma, 19, 617-621. https://doi.org/10.1097/IJG.0b013e3181ca7c7a
|
[27]
|
Rossi, G.C., Blini, M., Scudeller, L., Ricciardelli, G., Depolo, L., Amisano, A., Bossolesi, L., Pasinetti, G.M. and Bianchi, P.E. (2013) Effect of Preservative-Free Tafluprost on Keratocytes, Sub-Basal Nerves, and Endothelium: A Single-Blind One-Year Confocal Study on Naive or Treated Glaucoma and Hypertensive Patients versus a Control Group. Journal of Ocular Pharmacology and Therapeutics, 29, 821-825. https://doi.org/10.1089/jop.2013.0069
|
[28]
|
Ranno, S., Fogagnolo, P., Rossetti, L., Orzalesi, N. and Nucci, P. (2011) Changes in Corneal Parameters at Confocal Microscopy in Treated Glaucoma Patients. Clinical Ophthalmology (Auckland, NZ), 5, 1037-1042.
https://doi.org/10.2147/OPTH.S22874
|
[29]
|
Baratz, K.H., Nau, C.B., Winter, E.J., McLaren, J.W., Hodge, D.O., Herman, D.C. and Bourne, W.M. (2006) Effects of Glaucoma Medications on Corneal Endothelium, Keratocytes, and Subbasal Nerves among Participants in the Ocular Hypertension Treatment Study. Cornea, 25, 1046-1052. https://doi.org/10.1097/01.ico.0000230499.07273.c5
|
[30]
|
Martone, G., Frezzotti, P., Tosi, G.M., Traversi, C., Mittica, V., Malandrini, A., Pichierri, P., Balestrazzi, A., Motolese, P.A., Motolese, I. and Motolese, E. (2009) An in Vivo Confocal Microscopy Analysis of Effects of Topical Antiglaucoma Therapy with Preservative on Corneal Innervation and Morphology. American Journal of Ophthalmology, 147, 725-735.e721. https://doi.org/10.1016/j.ajo.2008.10.019
|
[31]
|
Labbe, A., Alalwani, H., Van Went, C., Brasnu, E., Georgescu, D. and Baudouin, C. (2012) The Relationship between Subbasal Nerve Morphology and Corneal Sensation in Ocular Surface Disease. Investigative Ophthalmology & Visual Science, 53, 4926-4931. https://doi.org/10.1167/iovs.11-8708
|
[32]
|
Villani, E., Sacchi, M., Magnani, F., Nicodemo, A., Williams, S.E., Rossi, A., Ratiglia, R., De Cilla, S. and Nucci, P. (2016) The Ocular Surface in Medically Controlled Glaucoma: An in Vivo Confocal Study. Investigative Ophthalmology & Visual Science, 57, 1003-1010. https://doi.org/10.1167/iovs.15-17455
|
[33]
|
Agnifili, L., Brescia, L., Oddone, F., Sacchi, M., D’Ugo, E., Di Marzio, G., Perna, F., Costagliola, C. and Mastropasqua, R. (2019) The Ocular Surface after Successful Glaucoma Filtration Surgery: A Clinical, in Vivo Confocal Microscopy, and Immune-Cytology Study. Scientific Reports, 9, Article No. 11299.
https://doi.org/10.1038/s41598-019-47823-z
|
[34]
|
Agnifili, L., Brescia, L., Villani, E., D’Onofrio, G., Figus, M., Oddone, F., Nucci, P. and Mastropasqua, R. (2022) In Vivo Confocal Microscopy of the Corneal Sub-Basal Nerve Plexus in Medically Controlled Glaucoma. Microscopy and Microanalysis, 1-8. https://doi.org/10.1017/S1431927621013969
|
[35]
|
Society, E.G. (2020) Terminology and Guidelines for Glaucoma. 5th Edition.
|
[36]
|
Bafa, M., Georgopoulos, G., Mihas, C., Stavrakas, P., Papaconstantinou, D. and Vergados, I. (2011) The Effect of Prostaglandin Analogues on Central Corneal Thickness of Patients with Chronic Open-Angle Glaucoma: A 2-Year Study on 129 Eyes. Acta Ophthalmologica, 89, 448-451. https://doi.org/10.1111/j.1755-3768.2009.01731.x
|
[37]
|
Duygu, U.U. (2018) The Effect of Prostaglandin Analogues on Central Corneal Thickness. International Journal of Ophthalmology and Clinical Research, 5, 84. https://doi.org/10.23937/2378-346X/1410084
|
[38]
|
Jang, M., Kang, K.E. and Cho, B.J. (2020) Effect of Prostaglandin Analogues on Central Corneal Thickness: 3-Year Follow-Up Results. Korean Journal of Ophthalmology: KJO, 34, 347-352. https://doi.org/10.3341/kjo.2019.0129
|
[39]
|
Lass, J., Eriksson, G., Osterling, L. and Simpson, C. (2001) Comparison of the Corneal Effects of Latanoprost, Fixed Combination Latanoprost-Timolol, and Timolol: A Double-Masked, Randomized, One-Year Study. Ophthalmology, 108, 264-271. https://doi.org/10.1016/S0161-6420(00)00531-5
|
[40]
|
Wierzbowska, J., Łagocka, A., Siemiatkowska, A., Robaszkiewicz, J., Stankiewicz, A. and Sierdziński, J. (2009) The Impact of Common Classes of Topical Antiglaucoma Medications on Central Corneal Thickness—Own Observations. Klinika Oczna, 111, 323-326.
|
[41]
|
Schwartz, G.S. and Holland, E.J. (1998) Iatrogenic Limbal Stem Cell Deficiency. Cornea, 17, 31-37.
https://doi.org/10.1097/00003226-199801000-00006
|
[42]
|
Liang, H., Baudouin, C., Pauly, A. and Brignole-Baudouin, F. (2008) Conjunctival and Corneal Reactions in Rabbits Following Short- and Repeated Exposure to Preservative-Free Tafluprost, Commercially Available Latanoprost and 0.02% Benzalkonium Chloride. British Journal of Ophthalmology, 92, 1275-1282.
https://doi.org/10.1136/bjo.2008.138768
|
[43]
|
Pauly, A., Roubeix, C., Liang, H., Brignole-Baudouin, F. and Baudouin, C. (2012) In Vitro and in Vivo Comparative Toxicological Study of a New Preservative-Free Latanoprost Formulation. Investigative Ophthalmology & Visual Science, 53, 8172-8180. https://doi.org/10.1167/iovs.12-10766
|
[44]
|
Mastropasqua, R., Agnifili, L., Fasanella, V., Curcio, C., Brescia, L., Lanzini, M., Fresina, M., Mastropasqua, L. and Marchini, G. (2015) Corneoscleral Limbus in Glaucoma Patients: In Vivo Confocal Microscopy and Immunocytological Study. Investigative Ophthalmology & Visual Science, 56, 2050-2058. https://doi.org/10.1167/iovs.14-15890
|
[45]
|
Mastropasqua, R., Agnifili, L., Fasanella, V., Lappa, A., Brescia, L., Lanzini, M., Oddone, F., Perri, P. and Mastropasqua, L. (2016) In Vivo Distribution of Corneal Epithelial Dendritic Cells in Patients with Glaucoma. Investigative Ophthalmology & Visual Science, 57, 5996-6002. https://doi.org/10.1167/iovs.16-20333
|
[46]
|
El Ameen, A., Vandermeer, G., Khanna, R.K. and Pisella, P.J. (2019) Objective Ocular Surface Tolerance in Patients with Glaucoma Treated with Topical Preserved or Unpreserved Prostaglandin Analogues. European Journal of Ophthalmology, 29, 645-653. https://doi.org/10.1177/1120672118805877
|
[47]
|
Hedengran, A., Steensberg, A.T., Virgili, G., Azuara-Blanco, A. and Kolko, M. (2020) Efficacy and Safety Evaluation of Benzalkonium Chloride Preserved Eye-Drops Compared with Alternatively Preserved and Preservative-Free Eye- Drops in the Treatment of Glaucoma: A Systematic Review and Meta-Analysis. British Journal of Ophthalmology, 104, 1512-1518. https://doi.org/10.1136/bjophthalmol-2019-315623
|
[48]
|
Moreno, M., Villena, A., Cabarga, C., Sanchez-Font, E. and Garcia-Campos, J. (2003) Impression Cytology of the Conjunctival Epithelium after Antiglaucomatous Treatment with Latanoprost. European Journal of Ophthalmology, 13, 553-559. https://doi.org/10.1177/112067210301300608
|
[49]
|
Ammar, D.A., Noecker, R.J. and Kahook, M.Y. (2010) Effects of Benzalkonium Chloride-Preserved, Polyquad-Preserved, and sofZia-Preserved Topical Glaucoma Medications on Human Ocular Epithelial Cells. Advances in Therapy, 27, 837-845. https://doi.org/10.1007/s12325-010-0070-1
|
[50]
|
Yang, Y., Huang, C., Lin, X., Wu, Y., Ouyang, W., Tang, L., Ye, S., Wang, Y., Li, W., Zhang, X. and Liu, Z. (2018) 0.005% Preservative-Free Latanoprost Induces Dry Eye-Like Ocular Surface Damage via Promotion of Inflammation in Mice. Investigative Ophthalmology & Visual Science, 59, 3375-3384. https://doi.org/10.1167/iovs.18-24013
|
[51]
|
Hedengran, A., Begun, X., Mullertz, O., Mouhammad, Z., Vohra, R., Bair, J., Dartt, D.A., Cvenkel, B., Heegaard, S., Petrovski, G. and Kolko, M. (2021) Benzalkonium Chloride-Preserved Anti-Glaucomatous Eye Drops and Their Effect on Human Conjunctival Goblet Cells in Vitro. Biomed Hub, 6, 69-75. https://doi.org/10.1159/000517845
|
[52]
|
Gipson, I.K. (2016) Goblet Cells of the Conjunctiva: A Review of Recent Findings. Progress in Retinal and Eye Research, 54, 49-63. https://doi.org/10.1016/j.preteyeres.2016.04.005
|
[53]
|
Mullertz, O., Hedengran, A., Mouhammad, Z.A., Freiberg, J., Nagymihaly, R., Jacobsen, J., Larsen, S.W., Bair, J., Utheim, T., Dartt, D.A., Heegaard, S., Petrovski, G. and Kolko, M. (2021) Impact of Benzalkonium Chloride-Pre- served and Preservative-Free Latanoprost Eye Drops on Cultured Human Conjunctival Goblet Cells upon Acute Exposure and Differences in Physicochemical Properties of the Eye Drops. BMJ Open Ophthalmology, 6, e000892.
https://doi.org/10.1136/bmjophth-2021-000892
|
[54]
|
Addicks, E.M., Quigley, H.A., Green, W.R. and Robin, A.L. (1983) Histologic Characteristics of Filtering Blebs in Glaucomatous Eyes. Archives of Ophthalmology, 101, 795-798.
https://doi.org/10.1001/archopht.1983.01040010795021
|
[55]
|
Amar, N., Labbe, A., Hamard, P., Dupas, B. and Baudouin, C. (2008) Filtering Blebs and Aqueous Pathway an Immunocytological and In Vivo Confocal Microscopy Study. Ophthalmology, 115, 1154-1161.e1154.
https://doi.org/10.1016/j.ophtha.2007.10.024
|
[56]
|
Ciancaglini, M., Carpineto, P., Agnifili, L., Nubile, M., Fasanella, V., Mattei, P.A. and Mastropasqua, L. (2009) Conjunctival Characteristics in Primary Open-Angle Glaucoma and Modifications Induced by Trabeculectomy with Mitomycin C: an In Vivo Confocal Microscopy Study. British Journal of Ophthalmology, 93, 1204-1209.
https://doi.org/10.1136/bjo.2008.152496
|
[57]
|
Staso, S.D., Agnifili, L., Gregorio, A.D. Climastone, H., Galassi, E., Fasanella, V. and Ciancaglini, M. (2017) Three- Dimensional Laser Scanning Confocal Analysis of Conjunctival Microcysts in Glaucomatous Patients before and after Trabeculectomy. In Vivo, 31, 1081-1088. https://doi.org/10.21873/invivo.11173
|
[58]
|
Ciancaglini, M., Carpineto, P., Agnifili, L., Nubile, M., Lanzini, M., Fasanella, V. and Mastropasqua, L. (2008) Filtering Bleb Functionality: A Clinical, Anterior Segment Optical Coherence Tomography and in Vivo Confocal Microscopy Study. Journal of Glaucoma, 17, 308-317. https://doi.org/10.1097/IJG.0b013e31815c3a19
|
[59]
|
Mastropasqua, L., Agnifili, L., Ciancaglini, M., Nubile, M., Carpineto, P., Fasanella, V., Figus, M., Lazzeri, S. and Nardi, M. (2010) In Vivo Analysis of Conjunctiva in Gold Micro Shunt Implantation for Glaucoma. British Journal of Ophthalmology, 94, 1592-1596. https://doi.org/10.1136/bjo.2010.179994
|
[60]
|
Agnifili, L., Carpineto, P., Fasanella, V., Mastropasqua, R., Zappacosta, A., Di Staso, S., Costagliola, C. and Mastropasqua, L. (2012) Conjunctival Findings in Hyperbaric and Low-Tension Glaucoma: An In Vivo Confocal Microscopy Study. Acta Ophthalmologica, 90, e132-e137. https://doi.org/10.1111/j.1755-3768.2011.02255.x
|
[61]
|
Mastropasqua, L., Agnifili, L., Salvetat, M.L., Ciancaglini, M., Fasanella, V., Nubile, M., Mastropasqua, R., Zeppieri, M. and Brusini, P. (2012) In Vivo Analysis of Conjunctiva in Canaloplasty for Glaucoma. British Journal of Ophthalmology, 96, 634-639. https://doi.org/10.1136/bjophthalmol-2011-301058
|
[62]
|
Mastropasqua, L., Agnifili, L., Mastropasqua, R., Fasanella, V., Nubile, M., Toto, L., Carpineto, P. and Ciancaglini, M. (2014) In Vivo Laser Scanning Confocal Microscopy of the Ocular Surface in Glaucoma. Microscopy and Microanalysis, 20, 879-894. https://doi.org/10.1017/S1431927614000324
|
[63]
|
Mastropasqua, R., Fasanella, V., Pedrotti, E., Lanzini, M., Di Staso, S., Mastropasqua, L. and Agnifili, L. (2014) Trans-Conjunctival Aqueous Humor Outflow in Glaucomatous Patients Treated with Prostaglandin Analogues: An In Vivo Confocal Microscopy Study. Graefe’s Archive for Clinical and Experimental Ophthalmology, 252, 1469-1476.
https://doi.org/10.1007/s00417-014-2664-9
|
[64]
|
Mastropasqua, R., Agnifili, L., Fasanella, V., Toto, L., Brescia, L., Di Staso, S., Doronzo, E. and Marchini, G. (2016) Uveo-Scleral Outflow Pathways after Ultrasonic Cyclocoagulation in Refractory Glaucoma: An Anterior Segment Optical Coherence Tomography and in Vivo Confocal Study. British Journal of Ophthalmology, 100, 1668-1675.
https://doi.org/10.1136/bjophthalmol-2015-308069
|
[65]
|
Ciancaglini, M., Carpineto, P., Agnifili, L., Nubile, M., Fasanella, V. and Mastropasqua, L. (2008) Conjunctival Modifications in Ocular Hypertension and Primary Open Angle Glaucoma: An In Vivo Confocal Microscopy Study. Investigative Ophthalmology & Visual Science, 49, 3042-3048. https://doi.org/10.1167/iovs.07-1201
|
[66]
|
Siebelmann, S., Gehlsen, U., Huttmann, G., Koop, N., Bolke, T., Gebert, A., Stern, M.E., Niederkorn, J.Y. and Steven, P. (2013) Development, Alteration and Real Time Dynamics of Conjunctiva-Associated Lymphoid Tissue. PLoS ONE, 8, e82355. https://doi.org/10.1371/journal.pone.0082355
|
[67]
|
Agnifili, L., Mastropasqua, R., Fasanella, V., Di Staso, S., Mastropasqua, A., Brescia, L. and Mastropasqua, L. (2014) In Vivo Confocal Microscopy of Conjunctiva-Associated Lymphoid Tissue in Healthy Humans. Investigative Ophthalmology & Visual Science, 55, 5254-5262. https://doi.org/10.1167/iovs.14-14365
|
[68]
|
Mastropasqua, R., Agnifili, L., Fasanella, V., Nubile, M., Gnama, A.A., Falconio, G., Perri, P., Di Staso, S. and Mariotti, C. (2017) The Conjunctiva-Associated Lymphoid Tissue in Chronic Ocular Surface Diseases. Microscopy and Microanalysis, 23, 697-707. https://doi.org/10.1017/S1431927617000538
|
[69]
|
Aydin Kurna, S., Acikgoz, S., Altun, A., Ozbay, N., Sengor, T. and Olcaysu, O.O. (2014) The Effects of Topical Antiglaucoma Drugs as Monotherapy on the Ocular Surface: A Prospective Study. Journal of Ophthalmology, 2014, Article ID: 460483. https://doi.org/10.1155/2014/460483
|
[70]
|
Cunniffe, M.G., Medel-Jimenez, R. and Gonzalez-Candial, M. (2011) Topical Antiglaucoma Treatment with Prostaglandin Analogues May Precipitate Meibomian Gland Disease. Ophthalmic Plastic & Reconstructive Surgery, 27, e128- e129. https://doi.org/10.1097/IOP.0b013e318201d32f
|
[71]
|
Mocan, M.C., Uzunosmanoglu, E., Kocabeyoglu, S., Karakaya, J. and Irkec, M. (2016) The Association of Chronic Topical Prostaglandin Analog Use with Meibomian Gland Dysfunction. Journal of Glaucoma, 25, 770-774.
https://doi.org/10.1097/IJG.0000000000000495
|
[72]
|
Cho, W.H., Lai, I.C., Fang, P.C., Chien, C.C., Tseng, S.L., Lai, Y.H., Huang, Y.T. and Kuo, M.T. (2018) Meibomian Gland Performance in Glaucomatous Patients with Long-Term Instillation of IOP-Lowering Medications. Journal of Glaucoma, 27, 176-183. https://doi.org/10.1097/IJG.0000000000000841
|
[73]
|
Arita, R., Itoh, K., Maeda, S., Maeda, K., Furuta, A., Tomidokoro, A., Aihara, M. and Amano, S. (2012) Effects of Long-Term Topical Anti-Glaucoma Medications on Meibomian Glands. Graefe’s Archive for Clinical and Experimental Ophthalmology, 250, 1181-1185. https://doi.org/10.1007/s00417-012-1943-6
|
[74]
|
Ha, J.Y., Sung, M.S. and Park, S.W. (2019) Effects of Preservative on the Meibomian Gland in Glaucoma Patients Treated with Prostaglandin Analogues. Chonnam Medical Journal, 55, 156-162.
https://doi.org/10.4068/cmj.2019.55.3.156
|
[75]
|
Wong, A.B.C., Wang, M.T.M., Liu, K., Prime, Z.J., Danesh-Meyer, H.V. and Craig, J.P. (2018) Exploring Topical Anti-Glaucoma Medication Effects on the Ocular Surface in the Context of the Current Understanding of Dry Eye. The Ocular Surface, 16, 289-293. https://doi.org/10.1016/j.jtos.2018.03.002
|
[76]
|
Su, C.C., Lee, Y.C. and Lee, P.R.C. (2021) Assessment of Ocular Surface Disease in Glaucoma Patients with Benzalkonium Chloride-Preserved Latanoprost Eye Drops: A Short-Term Longitudinal Study. Graefe’s Archive for Clinical and Experimental Ophthalmology, 259, 1243-1251. https://doi.org/10.1007/s00417-020-05067-y
|
[77]
|
Sedlak, L., Zych, M., Wojnar, W. and Wygledowska-Promienska, D. (2019) Effect of Topical Prostaglandin F2alpha Analogs on Selected Oxidative Stress Parameters in the Tear Film. Medicina (Kaunas), 55, 366.
https://doi.org/10.3390/medicina55070366
|
[78]
|
Hu, J., Vu, J.T., Hong, B. and Gottlieb, C. (2020) Uveitis and Cystoid Macular Oedema Secondary to Topical Prostaglandin Analogue Use in Ocular Hypertension and Open Angle Glaucoma. The British Journal of Ophthalmology, 104, 1040-1044. https://doi.org/10.1136/bjophthalmol-2019-315280
|
[79]
|
Massimo, L., Micelli Ferrari, L., Nikolopoulou Gisotti, E., Zito, R., MicelliFerrari, T., Anna, F. and Bordinone, M.A. (2021) Granulomatous Uveitis and Choroidal Detachment in a Patient after Topical Treatment with Bimatoprost: A Case Report. European Journal of Ophthalmology. https://doi.org/10.1177/1120672121990573
|
[80]
|
Holló, G., Aung, T., Cantor, L.B. and Aihara, M. (2020) Cystoid Macular Edema Related to Cataract Surgery and Topical Prostaglandin Analogs: Mechanism, Diagnosis, and Management. Survey of Ophthalmology, 65, 496-512.
https://doi.org/10.1016/j.survophthal.2020.02.004
|
[81]
|
Wu, G. and Morrell, A. (2000) Severe Hypotony Following Cataract Extraction in a Patient on Latanoprost. Eye, 14, 915-916. https://doi.org/10.1038/eye.2000.255
|
[82]
|
Gupta, R. and Vernon, S.A. (2001) Choroidal Detachment Following Extracapsular Cataract Extraction in a Patient Treated with Latanoprost. British Journal of Ophthalmology, 85, 1268. https://doi.org/10.1136/bjo.85.10.1260i
|
[83]
|
Marques Pereira, M.L. and Katz, L.J. (2001) Choroidal Detachment after the Use of Topical Latanoprost. American Journal of Ophthalmology, 132, 928-929. https://doi.org/10.1016/S0002-9394(01)01143-6
|
[84]
|
Sodhi, P.K., Sachdev, M.S., Gupta, A., Verma, L.K. and Ratan, S.K. (2004) Choroidal Detachment with Topical Latanoprost after Glaucoma Filtration Surgery. Annals of Pharmacotherapy, 38, 510-511.
https://doi.org/10.1345/aph.1D281
|
[85]
|
Pathanapitoon, K. and Kunavisarut, P. (2005) Choroidal Detachment after Topical Prostaglandin Analogs: Case Report. Journal of the Medical Association of Thailand, 88, 1134-1136.
|
[86]
|
Cheggour, M. and Gambrelle, J. (2012) Massive Choroidal Detachment Secondary to Topical Use of Bimatoprost: Report of Two Cases. Journal Francais D’ophtalmologie, 35, 176-180. https://doi.org/10.1016/j.jfo.2011.09.009
|
[87]
|
Sakai, H., Sakima, N., Nakamura, Y., Nakamura, Y., Hayakawa, K. and Sawaguchi, S. (2002) Ciliochoroidal Effusion Induced by Topical Latanoprost in a Patient with Sturge-Weber Syndrome. Japanese Journal of Ophthalmology, 46, 553-555. https://doi.org/10.1016/S0021-5155(02)00542-7
|
[88]
|
Gambrelle, J., Denis, P., Kocaba, V. and Grange, J.D. (2008) Uveal Effusion Induced by Topical Travoprost in a Patient with Sturge-Weber-Krabbe Syndrome. Journal Francais D’ophtalmologie, 31, e19.
https://doi.org/10.1016/S0181-5512(08)74730-2
|
[89]
|
Romano, M.R. and Lograno, M.D. (2007) Evidence for the Involvement of Cannabinoid CB1 Receptors in the Bimatoprost-Induced Contractions on the Human Isolated Ciliary Muscle. Investigative Ophthalmology & Visual Science, 48, 3677-3682. https://doi.org/10.1167/iovs.06-0896
|
[90]
|
Ayaki, M., Tsuneyoshi, Y., Yuki, K., Tsubota, K. and Negishi, K. (2019) Latanoprost Could Exacerbate the Progression of Presbyopia. PLoS ONE, 14, e0211631. https://doi.org/10.1371/journal.pone.0211631
|
[91]
|
Alphen, G.W., Wilhelm, P.B. and Elsenfeld, P.W. (1977) The Effect of Prostaglandins on the Isolated Internal Muscles of the Mammalian Eye, Including Man. Documenta Ophthalmologica, 42, 397-415.
https://doi.org/10.1007/BF02742255
|
[92]
|
Crawford, K.S. and Kaufman, P.L. (1991) Dose-Related Effects of Prostaglandin F2 Alpha Isopropylester on Intraocular Pressure, Refraction, and Pupil Diameter in Monkeys. Investigative Ophthalmology & Visual Science, 32, 510-519.
|
[93]
|
Millar, J.C. and Kaufman, P.L. (1995) PGF2 Alpha/Pilocarpine Interactions on IOP and Accommodation in Monkeys. Experimental Eye Research, 61, 677-683. https://doi.org/10.1016/S0014-4835(05)80018-1
|
[94]
|
Otsuka, N., Yoshitomi, T., Tsuchiya, K., Ukai, K., Ooki, C. and Ishikawa, S. (1996) Effects of Topical Application of Isopropyl Unoprostone on Refraction and Accommodation. Nippon Ganka Gakkai Zasshi, 100, 531-534.
|
[95]
|
Troiano, P., Oldani, A., Gozzini, C., Iraci, M., Dalpozzo, R., Baratta, M. and De Mattia, M. (2000) Latanoprost 0.005%: Evaluation of Its Effect on Accommodative Capacity. Acta ophthalmologica Scandinavica. Supplement, 232, 52-54. https://doi.org/10.1111/j.1600-0420.2000.tb01104.x
|
[96]
|
Kurtz, S., Leibovitch, I., Shemesh, G., Rothkoff, L. and Loewenstein, A. (2003) The Effect of Latanoprost on Accommodation in Young Patients with Ocular Hypertension. Journal of Glaucoma, 12, 54-56.
https://doi.org/10.1097/00061198-200302000-00011
|
[97]
|
Bhat, S., Handa, S. and De, D. (2021) A Randomized Comparative Study of the Efficacy of Topical Latanoprost versus Topical Betamethasone Diproprionate Lotion in the Treatment of Localized Alopecia Areata. Indian Journal of Dermatology, Venereology and Leprology, 87, 42-48. https://doi.org/10.25259/IJDVL_787_19
|
[98]
|
Johnstone, M.A. (1997) Hypertrichosis and Increased Pigmentation of Eyelashes and Adjacent Hair in the Region of the Ipsilateral Eyelids of Patients Treated with Unilateral Topical Latanoprost. American Journal of Ophthalmology, 124, 544-547. https://doi.org/10.1016/S0002-9394(14)70870-0
|
[99]
|
Steinsapir, K.D. and Steinsapir, S.M.G. (2021) Revisiting the Safety of Prostaglandin Analog Eyelash Growth Products. Dermatologic Surgery: Official Publication for American Society for Dermatologic Surgery, 47, 658-665.
https://doi.org/10.1097/DSS.0000000000002928
|
[100]
|
Esaki, Y., Katsuta, O., Kamio, H., Noto, T., Mano, H., Iwamura, R., Yoneda, K., Odani-Kawabata, N., Morishima, K. and Shams, N.K. (2020) The Antiglaucoma Agent and EP2 Receptor Agonist Omidenepag Does Not Affect Eyelash Growth in Mice. Journal of Ocular Pharmacology and Therapeutics: The Official Journal of the Association for Ocular Pharmacology and Therapeutics, 36, 529-533. https://doi.org/10.1089/jop.2020.0003
|
[101]
|
Peplinski, L.S. and Albiani Smith, K. (2004) Deepening of Lid Sulcus from Topical Bimatoprost Therapy. Optometry and Vision Science, 81, 574-577. https://doi.org/10.1097/01.opx.0000141791.16683.4a
|
[102]
|
Yang, H.K., Park, K.H., Kim, T.W. and Kim, D.M. (2009) Deepening of Eyelid Superior Sulcus during Topical Travoprost Treatment. Japanese Journal of Ophthalmology, 53, 176-179. https://doi.org/10.1007/s10384-008-0623-x
|
[103]
|
Jayaprakasam, A. and Ghazi-Nouri, S. (2010) Periorbital Fat Atrophy—An Unfamiliar Side Effect of Prostaglandin Analogues. Orbit, 29, 357-359. https://doi.org/10.3109/01676830.2010.527028
|
[104]
|
Nakakura, S., Tabuchi, H. and Kiuchi, Y. (2011) Latanoprost Therapy after Sunken Eyes Caused by Travoprost or Bimatoprost. Optometry and Vision Science, 88, 1140-1144. https://doi.org/10.1097/OPX.0b013e3182231202
|
[105]
|
Park, J., Cho, H.K. and Moon, J.I. (2011) Changes to Upper Eyelid Orbital Fat from Use of Topical Bimatoprost, Travoprost, and Latanoprost. Japanese Journal of Ophthalmology, 55, 22. https://doi.org/10.1007/s10384-010-0904-z
|
[106]
|
Inoue, K., Shiokawa, M., Wakakura, M. and Tomita, G. (2013) Deepening of the Upper Eyelid Sulcus Caused by 5 Types of Prostaglandin Analogs. Journal of Glaucoma, 22, 626-631. https://doi.org/10.1097/IJG.0b013e31824d8d7c
|
[107]
|
Kucukevcilioglu, M., Bayer, A. and Uysal, Y. (2014) Prostaglandin Associated Periorbitopathy in Patients Using Bimatoprost, Latanoprost and Travoprost. Clinical & Experimental Ophthalmology, 42, 126-131.
https://doi.org/10.1111/ceo.12163
|
[108]
|
Sakata, R., Shirato, S. and Miyata, K. (2014) Incidence of Deepening of the Upper Eyelid Sulcus on Treatment with a Tafluprost Ophthalmic Solution. Japanese Journal of Ophthalmology, 58, 212-217.
https://doi.org/10.1007/s10384-013-0299-8
|
[109]
|
Sarnoff, D.S. and Gotkin, R.H. (2015) Bimatoprost-Induced Chemical Blepharoplasty. Journal of Drugs in Dermatology, 14, 472-477.
|
[110]
|
Sakata, R., Fujishiro, T. and Saito, H. (2021) Recovery of Deepening of the Upper Eyelid Sulcus after Switching from Prostaglandin FP Receptor Agonists to EP2 Receptor Agonist: A 3-Month Prospective Analysis. Japanese Journal of Ophthalmology, 65, 591-597. https://doi.org/10.1007/s10384-021-00855-3
|
[111]
|
Hikage, F., Ida, Y. and Ouchi, Y. (2021) Omidenepag, a Selective, Prostanoid EP2 Agonist, Does Not Suppress Adipogenesis in 3D Organoids of Human Orbital Fibroblasts. Translational Vision Science & Technology, 10, 6.
https://doi.org/10.1167/tvst.10.4.6
|
[112]
|
Oogi, S., Nakakura, S. and Terao, E. (2020) One-Year Follow-Up Study of Changes in Prostaglandin-Associated Periorbital Syndrome after Switch from Conventional Prostaglandin F2alfa to Omidenepag Isopropyl. Cureus, 12, e10064.
https://doi.org/10.7759/cureus.10064
|
[113]
|
Wang, H., Masselos, K., Kalloniatis, M. and Phu, J. (2021) Headaches Related to Latanoprost in Open-Angle Glaucoma. Clinical and Experimental Optometry, 104, 625-633. https://doi.org/10.1080/08164622.2021.1878846
|
[114]
|
Headache Classification Committee of the International Headache Society (IHS) (2018) The International Classification of Headache Disorders, 3rd Edition. Cephalalgia, 38, 1-211. https://doi.org/10.1177/0333102417738202
|
[115]
|
Weston, B.C. (2001) Migraine Headache Associated with Latanoprost. Archives of Ophthalmology, 119, 300-301.
|
[116]
|
Olesen, J., Burstein, R., Ashina, M. and Tfelt-Hansen, P. (2009) Origin of Pain in Migraine: Evidence for Peripheral Sensitisation. The Lancet Neurology, 8, 679-690. https://doi.org/10.1016/S1474-4422(09)70090-0
|
[117]
|
(MHRA) M.a.H.p.R.A. (2011) Latanoprost Drug Analysis Print, 7 May 2011.
http://www.mhra.gov.uk/home/groups/public/documents
/sentineldocuments/dap_1306406731772.pdf
|
[118]
|
De Smit, E., Theodorou, M., Hildebrand, G.D. and Bloom, P. (2011) Heart Block Following Topical Latanoprost Treatment. BMJ Case Reports, 2011, bcr0820114607. https://doi.org/10.1136/bcr.08.2011.4607
|